Hims & Hers Health, Inc. (HIMS) Key Metrics
HIMS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.55B
- Enterprise value
- $7.33B
- P/E (TTM)
- —
- Forward P/E
- 73.5
- PEG ratio
- 2.59
- Price / sales
- 2.5 10-yr median 3.6
- Price / book
- 20.4 10-yr median 5.4
- EV / EBITDA
- 205.9
- Dividend yield
- —
- Beta
- 2.43
HIMS key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsHIMS valuation Price multiples at each fiscal year-end price.
HIMS returns How much profit the business earns on the capital it uses.
HIMS per-share figures Results divided by the shares outstanding at year-end.
HIMS financial health Debt, liquidity and how easily interest is covered.
HIMS efficiency & capital use Working capital cycle and where the cash goes.
HIMS valuation history
HIMS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HIMS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HIMS cash returned to shareholders
HIMS price vs earnings per share
HIMS key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $8.38B | $5.73B | $1.86B | $1.31B | $1.22B | — | — | — |
| Enterprise value | $8.93B | $5.44B | $1.65B | $1.14B | $981.6M | — | — | — |
| P/E ratio | 65.3 | 45.4 | — | — | — | — | — | — |
| Price / sales | 3.6 | 3.9 | 2.1 | 2.5 | 4.5 | — | — | — |
| Price / book | 15.5 | 12.0 | 5.4 | 4.2 | 3.7 | — | — | — |
| Price / free cash flow | 113.4 | 28.9 | 39.6 | — | — | — | — | — |
| Price / operating cash flow | 27.9 | 22.8 | 25.4 | — | — | — | — | — |
| EV / sales | 3.8 | 3.7 | 1.9 | 2.2 | 3.6 | — | — | — |
| EV / EBITDA | 50.0 | 61.2 | — | — | — | — | — | — |
| EV / free cash flow | 120.7 | 27.4 | 35.2 | — | — | — | — | — |
| Earnings yield | 1.5% | 2.2% | −1.3% | −5.0% | −8.8% | — | — | — |
| Free cash flow yield | 0.9% | 3.5% | 2.5% | −2.6% | −3.2% | — | — | — |
| Shareholder yield (dividends + buybacks) | 1.1% | 1.5% | 0.1% | 0.3% | 1.8% | — | — | — |
| Share price at fiscal year-end | $32.47 | $24.18 | $8.90 | $6.41 | $6.55 | $14.60 | $9.90 | — |
| Per share | ||||||||
| Revenue per share | $9.09 | $6.24 | $4.17 | $2.58 | $1.46 | — | — | $0.40 |
| Earnings per share | $0.50 | $0.53 | −$0.11 | −$0.32 | −$0.58 | — | — | −$1.12 |
| Operating cash flow per share | $1.16 | $1.06 | $0.35 | −$0.13 | −$0.18 | — | — | −$0.85 |
| Free cash flow per share | $0.29 | $0.84 | $0.22 | −$0.17 | −$0.21 | — | — | −$0.85 |
| Cash per share | $2.24 | $1.27 | $1.06 | $0.88 | $1.32 | — | — | $0.62 |
| Book value per share | $2.09 | $2.01 | $1.64 | $1.52 | $1.79 | — | — | $0.34 |
| Tangible book value per share | $0.26 | $1.35 | $1.02 | $0.88 | $1.06 | — | — | $0.34 |
| Capex per share | $0.88 | $0.22 | $0.13 | $0.04 | $0.03 | — | — | $0.00 |
| Debt per share | $4.34 | $0.05 | $0.05 | $0.03 | $0.03 | — | — | $0.12 |
| Shares outstanding | 258.2M | 236.8M | 209.3M | 204.5M | 186.8M | — | — | 67.3M |
| Change in shares outstanding | +9.0% | +13.1% | +2.4% | +9.5% | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | 25.2% | 30.7% | −7.2% | −20.3% | −114.7% | — | — | −330.1% |
| Return on invested capital (ROIC) | 16.6% | 38.6% | −17.2% | −47.1% | — | — | — | — |
| Return on assets (ROA) | 9.0% | 21.9% | −5.8% | −16.7% | −39.9% | −19.0% | −120.5% | −158.3% |
| Return on tangible assets | 7.6% | 22.9% | −7.6% | −28.1% | −37.9% | −15.3% | −101.8% | −158.3% |
| Free cash flow margin | 3.2% | 13.4% | 5.4% | −6.4% | −14.5% | −4.5% | −92.8% | −214.9% |
| Income quality (OCF / net income) | 2.34 | 1.99 | — | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | $1.12B | $11.3M | $9.9M | $5.3M | $5.5M | $4.3M | $1.5M | $8.4M |
| Cash & short-term investments | $577.5M | $300.3M | $221.0M | $179.6M | $247.3M | $100.2M | $60.4M | $41.5M |
| Net debt | $543.1M | −$288.9M | −$211.0M | −$174.3M | −$241.8M | −$95.9M | −$58.9M | −$33.1M |
| Debt / equity | 2.07 | 0.02 | 0.03 | 0.02 | 0.02 | — | — | 0.37 |
| Debt / assets | 0.52 | 0.02 | 0.02 | 0.01 | 0.01 | 0.04 | 0.02 | 0.18 |
| Net debt / EBITDA | 3.04 | −3.25 | — | — | — | — | — | — |
| Current ratio | 1.90 | 1.79 | 3.00 | 4.52 | 3.41 | 7.43 | 3.38 | 1.96 |
| Quick ratio | 1.61 | 1.50 | 2.74 | 4.07 | 3.24 | 7.19 | 3.17 | 1.81 |
| Interest coverage | — | — | — | -23.0 | -30.3 | — | -201.7 | — |
| Working capital | $363.2M | $174.5M | $176.6M | $168.7M | $190.7M | $97.9M | $49.0M | $23.2M |
| Invested capital | $1.08B | $187.8M | $133.0M | $137.4M | $92.8M | −$242.8M | −$194.1M | −$10.3M |
| Tangible asset value | $66.5M | $320.6M | $214.6M | $179.0M | $197.8M | −$146.9M | −$136.6M | $22.8M |
| Net current asset value | −$846.1M | $165.0M | $167.9M | $162.0M | $183.9M | −$152.5M | −$137.8M | $22.6M |
| Graham number | $4.84 | $4.91 | — | — | — | — | — | — |
| Graham net-net per share | −$3.70 | $0.45 | $0.67 | $0.68 | $0.91 | — | — | $0.28 |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | — | $1.7M | — | — |
| Share buybacks (net) | $90.0M | $83.0M | $2.0M | $3.9M | $22.0M | $22.0M | $0 | — |
| Dividends + buybacks / free cash flow | 121.6% | 41.9% | 4.3% | — | — | — | — | — |
| Capex / revenue | 9.6% | 3.6% | 3.0% | 1.4% | 1.8% | 2.8% | 2.2% | 0.0% |
| Capex / operating cash flow | 75.3% | 21.0% | 36.1% | — | — | — | — | — |
| Capex / depreciation | 4.15 | 3.09 | 2.78 | 0.97 | 1.23 | 4.00 | 6.87 | 0.03 |
| Stock-based compensation / revenue | 5.8% | 6.3% | 7.6% | 8.1% | 24.7% | 3.9% | 9.7% | 27.4% |
| R&D / revenue | 6.4% | 5.3% | 5.5% | 5.5% | 8.2% | 7.6% | — | — |
| SG&A / revenue | 50.8% | 57.3% | 66.1% | 70.4% | 91.8% | 76.2% | 144.2% | 313.3% |
| Efficiency | ||||||||
| Days sales outstanding | 3.0 | 1.6 | 2.1 | 2.4 | 2.9 | 2.0 | 3.0 | 6.8 |
| Days of inventory on hand | 53.5 | 52.3 | 51.2 | 54.2 | 46.3 | 36.0 | 38.0 | 71.4 |
| Days payables outstanding | 69.7 | 80.8 | 87.7 | 80.3 | 75.0 | 71.0 | 98.8 | 257.3 |
| Cash conversion cycle (days) | -13.2 | -26.9 | -34.4 | -23.7 | -25.8 | -33.0 | -57.7 | -179.0 |
| Receivables turnover | 122.82 | 230.20 | 174.77 | 154.79 | 125.67 | 184.91 | 121.59 | 53.46 |
| Payables turnover | 5.24 | 4.52 | 4.16 | 4.55 | 4.86 | 5.14 | 3.70 | 1.42 |
| Inventory turnover | 6.82 | 6.98 | 7.13 | 6.73 | 7.88 | 10.13 | 9.59 | 5.11 |
| Asset turnover | 1.64 | 2.57 | 2.16 | 1.34 | 1.01 | 1.56 | 1.38 | 0.56 |
| Average receivables | $19.1M | $6.4M | $5.0M | $3.4M | $2.2M | $804,500 | $679,000 | $499,000 |
| Average payables | $117.2M | $67.1M | $37.7M | $26.0M | $13.9M | $7.6M | $10.3M | $13.3M |
| Average inventory | $90.1M | $43.4M | $22.0M | $17.6M | $8.6M | $3.9M | $4.0M | $3.7M |
| Intangibles / total assets | 22.0% | 22.1% | 29.3% | 36.2% | 32.5% | 0.0% | 1.8% | 0.0% |
Computed from HIMS's annual financial statements (latest annual report filed February 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HIMS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Hims & Hers Health traded at 65.3 times earnings. Hims & Hers Health earned a return on equity of 25.2% and a return on invested capital of 16.6% in fiscal 2025. It ended the year with $1.1 billion of debt and $577.5 million in cash and short-term investments, net debt of $543.1 million. It returned $90.0 million to shareholders: $0 in dividends and $90.0 million in share buybacks, 122% of free cash flow. The share count rose 283.7% from 67.3M to 258.2M over 7 years.
See the HIMS income statement, the HIMS chart for price history, or the HIMS stock overview for the latest quote and news.
HIMS key metrics FAQ
What is Hims & Hers Health's P/E ratio?
Hims & Hers Health traded at 65.3 times earnings at the end of fiscal 2025.
What is Hims & Hers Health's EV/EBITDA?
Hims & Hers Health's enterprise value was 50.0 times EBITDA at the end of fiscal 2025 (enterprise value $8.9 billion, EBITDA $178.4 million); the current EV/EBITDA is 205.9.
What is Hims & Hers Health's return on equity?
Hims & Hers Health's return on equity (ROE) was 25.2% in fiscal 2025: net income of $128.4 million on average shareholders' equity of $508.8 million.
What is Hims & Hers Health's ROIC?
Hims & Hers Health's return on invested capital was 16.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Hims & Hers Health have?
Hims & Hers Health had total debt of $1.1 billion at the end of fiscal 2025, a debt-to-equity ratio of 2.07 and $543.1 million of net debt (3.04 times EBITDA).
Does Hims & Hers Health buy back its shares?
Yes. Hims & Hers Health spent $90.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +9.0% over the year, to 258.2M..
What is Hims & Hers Health's free cash flow yield?
Hims & Hers Health generated $74.0 million of free cash flow in fiscal 2025, a free cash flow yield of 0.9% on its market value at year-end ($8.4 billion).
What is Hims & Hers Health's current ratio?
Hims & Hers Health's current ratio was 1.90 at the end of fiscal 2025: current assets were 1.90 times current liabilities.